Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer
August 5, 2026 6:33 AM
Oppenheimer analyst Matthew Hershenhorn raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $25.00 (from $23.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
